Publication: Gut microbiota characteristics in children after the use of proton pump inhibitors
Issued Date
2021-01-01
Resource Type
ISSN
21485607
13004948
13004948
Other identifier(s)
2-s2.0-85105280521
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Turkish Journal of Gastroenterology. Vol.32, No.1 (2021), 70-75
Suggested Citation
Lila Simakachorn, Pornthep Tanpowpong, Suwanee Chanprasertyothin, Supranee Thongpradit, Suporn Treepongkaruna Gut microbiota characteristics in children after the use of proton pump inhibitors. Turkish Journal of Gastroenterology. Vol.32, No.1 (2021), 70-75. doi:10.5152/tjg.2020.20245 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/78756
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Gut microbiota characteristics in children after the use of proton pump inhibitors
Other Contributor(s)
Abstract
Background/Aims: Prolonged acid suppression from proton pump inhibitor (PPI) has been shown to cause gut microbiota alteration, which may increase the risk of various infections in adults. We aimed to characterize gut microbiota profiles in children after a short-term use of PPI. Materials and Methods: Children aged 1-18 years who underwent PPI therapy were included during April-December 2017. We excluded children who previously used antibiotics or acid suppressants and who had a history of acute gastroenteritis or specific food avoidance one month prior to the enrolment. The stool samples before and after the PPI use were collected for gut microbiota composition. The 16S ribosomal RNA gene sequencing was performed by using Illumina MiSeq. The differences in the gut microbiota profile after the use of PPI were compared to pre-PPI period. Results: We completed stool collection in 20 children (median age of 5.8 years and 60% were female). No significant changes in the overall number of species-level taxonomy categories or predominant bacteria belonging to the phylum (Bacteroidetes) were noted. We found a trend increase in the proportion of the phylum Firmicutes among children living in the designated metropolitan/suburban area (P =.07) and among males (P =.11). In four children with infection-related adverse effects, we noted a nonsignificant increase in the proportion of the phylum Firmicutes after the PPI use (from 35% to 52%, P =.14). Conclusions: Even the total number of and predominant gut microbiota did not significantly change after a four- to eight-week course of PPI therapy; we found a trend of increase in the proportion of the phylum Firmicutes in certain groups of children.